Multiple Sclerosis Therapeutics to 2019 - a new market research report on companiesandmarkets.com
PR-Inside.com: 2014-04-28 03:58:01
The MS therapeutics market (Multiple Sclerosis) has been growing consistently over the last two decades and is forecast to continue to grow from $8.1 billion in 2012 to $17.6 billion by 2019 at a CAGR of 11.6%. Currently there are a number of disease-modifying drugs in the Multiple Sclerosis (MS) market that are indicated for the treatment of relapsing forms of the disease, specifically reducing the frequency of disease relapses.
The market is led by Copaxone, which achieved global sales of $4 billion in 2012. Over the forecast period 2012â2019, a variety of new drugs are due to enter the market that will offer a vast improvement in efficacy but also convenience, as many of these drugs are orally administered.
Additionally, a high number of monoclonal Antibodies (mAbs) are due to enter the market and diversify it in terms of its portfolio for late stage or aggressive MS. All of these drugs have been shown to offer substantial improvements over current therapies. The price of these new therapies is expected to be high, particularly for the mAbs, but this is unlikely to hinder their uptake.
The US will remain the biggest market, constituting approximately 65% of the total by 2019, although this represents little change in the intervening years. Despite some countries in the EU growing more slowly in terms of prevalence than others (such as Germany and Spain), the European market in general will grow due to population growth and subsequent patient-population growth, higher drug prices, and strong uptake due to more expensive and efficacious pipeline drugs. Japan will remain of little significance owing to the very low prevalence population and continued negligible percentage of the overall market, despite high drug prices.
The overall pipeline for MS is strong, with multiple molecules of varying classes and targets across all stages of development. It should be of particular note that of the 228 molecules in the MS pipeline, 112 are in the preclinical stage with many of these drugs targeting novel proteins or employing novel mechanisms of action. This is also true of Phases I and II, respectively.
Late-stage drugs are of particular interest due to the large number of oral drugs currently occupying both Phases II and III. These drugs appear to offer a profound improvement over the currently available treatments (as previously outlined). This plethora of diverse drugs should result in yet more improvements in the standard of therapy available to patients with MS in the future.
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.